What the physician needs to know for correct management of gastrooesophageal reflux disease and dyspepsia

Alimentary Pharmacology and Therapeutics

Volumn 20, Issue SUPPL.2, 2004, Pages 23-30

  Talley, N J ^a,b  

^a Mayo Clinic   (United States)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ACETYLSALICYLIC ACID; ALENDRONIC ACID; CYCLOOXYGENASE 2 INHIBITOR; ERYTHROMYCIN; HISTAMINE H2 RECEPTOR ANTAGONIST; INDOMETACIN; MECLOFENAMIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PIROXICAM; POTASSIUM; PROTON PUMP INHIBITOR; RISEDRONIC ACID; TETRAHYDROLIPSTATIN; THEOPHYLLINE;

CLINICAL FEATURE; CONFERENCE PAPER; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DRUG EFFICACY; DYSPEPSIA; ESOPHAGUS PH; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL TRACT FUNCTION; HEARTBURN; HELICOBACTER INFECTION; HUMAN; PEPTIC ULCER; PH MEASUREMENT; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RISK ASSESSMENT; STOMACH ACID SECRETION; SYMPTOMATOLOGY; TREATMENT OUTCOME;

EID: 4544349208     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2004.02043.x     Document Type: Conference Paper

References (80)

1. Talley NJ. Dyspepsia. Gastroenterology 2003; 125: 1219-26.
2. Talley NJ. Dyspepsia management in the millennium: the death of test and treat? Gastroenterology 2002; 122: 1521-5.
3. El-Serag HB, Talley NJ. The prevalence and clinical course of functional dyspepsia. Aliment Pharmacol Ther 2004; 19: 643-54.
4. Westbrook JI, Talley NJ. Diagnostic investigation rates and use of prescription and non-prescription medications amongst dyspeptics: a population-based study of 2300 Australians. Aliment Pharmacol Ther 2003; 17: 1171-8.
5. Talley NJ, Silverstein MD, Agreus L, Nyren O, Sonnenberg A, Holtmann G. AGA technical review: evaluation of dyspepsia. American Gastroenterological Association. Gastroenterol 1998; 114: 582-95.
6. Talley NJ, Axon A, Bytzer P, Holtmann G, Lam SK, Van Zanten S. Management of uninvestigated and functional dyspepsia: a Working Party report for the World Congresses of Gastroenterology 1998. Aliment Pharmacol Ther 1999; 13: 1135-48.
7. Talley NJ, Lam SK, Goh KL, Fock KM. Management guidelines for uninvestigated and functional dyspepsia in the Asia-Pacific region: First Asian Pacific Working Party on functional dyspepsia. J Gastroenterol Hepatol 1998; 13: 335-53.
8. Delaney BC, Moayyedi P, Forman D. Initial management strategies for dyspepsia. Cochrane Database Syst Rev 2003; 2: CD001961.
9. Thomson AB, Barkun AN, Armstrong D, et al. The prevalence of clinically significant endoscopie findings in primary care patients with uninvestigated dyspepsia: the Canadian Adult Dyspepsia Empiric Treatment - Prompt Endoscopy (CADET-PE) study. Aliment Pharmacol Ther 2003; 17: 1481-91.
10. Heikkinen M, Pikkarainen P, Takala J, Rasanen H, Julkunen R. Etiology of dyspepsia: four hundred unselected consecutive patients in general practice. Scand J Gastroenterol 1995; 30: 519-23.
11. Talley NJ, O'Connor S. Clinical Examination. A Systematic Guide to Physical Diagnosis. 4th edn. Blackwell Science: Oxford, 2001.
12. Locke GR, 3rd Talley NJ, Fett SL, Zinsmeister AR, Melton LJ III. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997; 112: 1448-56.
13. Meineche-Schmidt V, Jorgensen T. 'Alarm symptoms' in patients with dyspepsia: a three-year prospective study from general practice. Scand J Gastroenterol 2002; 37: 999-1007.
14. Christie J, Shepherd NA, Codling BW, et al. Gastric cancer below the age of 55: implications for screening patients with uncomplicated dyspepsia. Gut 1997; 41: 513-7.
15. Gillen D, McColl KE. Does concern about missing malignancy justify endoscopy in uncomplicated dyspepsia in patients aged less than 55? Am J Gastroenterol 1999; 94: 2329-30.
16. Canga C. III, Vakil N. Upper GI malignancy, uncomplicated dyspepsia, and the age threshold for early endoscopy. Am J Gastroenterol 2002; 97: 600-3.
17. Breslin NP, Thomson AB, Bailey RJ, et al. Gastric cancer and other endoscopic diagnoses in patients with benign dyspepsia. Gut 2000; 46: 93-7.
18. Numans ME, van der Graaf Y, de Wit NJ, de Melker RA. How useful is selection based on alarm symptoms in requesting gastroscopy? Scan J Gastroenterol 2001; 36: 437-43.
19. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 1999; 94: 1434-42.
20. Laine L. The gastrointestinal effects of nonselective NSAIDs and COX-2-selective inhibitors. Semin Arthritis Rheum 2002; 32 (Suppl. 1): 25-32.
21. Kimmey MB, Lanas A. Appropriate use of proton pump inhibitors with traditional nonsteroidal anti-inflammatory drugs and COX-2 selective inhibitors [Review]. Aliment Pharmacol Ther 2004; 19 (Suppl. 1): 60-5.
22. Ofman JJ, Maclean CH, Straus WL, et al. Meta-analysis of dyspepsia and nonsteroidal antiinflammatory drugs. Arthritis Rheum 2003; 49: 508-18.
23. Hart JD, Hawkey CJ, Lanas AI, et al. Predictors of gastroduodenal erosions in patients taking low-dose aspirin: H. pylori protectds the stomach but not the duodenum [Abstract]. Gastroenterology 2003; 124 (Suppl. 1): A108.
24. Holtmann G, Gschossmann J, Buenger L, Gerken G, Talley NJ. Do changes in visceral sensory function determine the development of dyspepsia during treatment with aspirin? Gastroenterology 2002; 123: 1451-8.
25. Thomson AB, Marshall JK, Hunt RH, et al. 14 day endoscopy study comparing risedronate and alendronate in post-menopausal women stratified by Helicobacter pylori status. J Rheumatol 2002; 29: 1965-74.
26. Hallas J, Bytzer P. Screening for drug related dyspepsia: an analysis of prescription symmetry. Eur J Gastroenterol Hepatol 1998; 10: 27-32.
27. Talley NJ, Stanghellini V, Heading RC, Koch KL, Malagelada JR, Tytgat GN. Functional gastroduodenal disorders. Gut 1999; 45 (Suppl. II): 37-42.
28. Moayyedi P, Axon A. The usefulness of the likelihood ratio in the diagnosis of dyspepsia gastroesophageal reflux disease. Am J Gastroenterol 1999; 94: 3122-5.
29. Anonymous. An evidence-based appraisal of reflux disease management - the Genval Workshop Report. Gut 1999; 44 (Suppl. 2): S1-16.
30. Locke GR, Zinsmeister AR, Talley NJ. Can symptoms predict endoscopic findings in GERD? Gastrointest Endosc 2003; 58: 661-70.
31. Avidan B, Sonnenberg A, Schnell TG, Sontag SJ. There are no reliable symptoms for erosive oesophagitis and Barrett's oesophagus: endoscopic diagnosis is still essential. Aliment Pharmacol Ther 2002; 16: 735-42.
32. Katelaris P, Holloway R, Talley N, Gotley D, Williams S, Dent J. Gastro-oesophageal reflux disease in adults: guidelines for clinicians. Digestive Health Foundation of the Gastroenterological Society of Australia. J Gastroenterol Hepatol 2002; 17: 825-33.
33. Bolling-Sternevald E, Carlsson R, Aalykke C, et al. Self-administered symptom questionnaires in patients with dyspepsia and their yield in discriminating between endoscopic diagnoses. Dig Dis 2002; 20: 191-8.
34. Wallace MB, Durkalski VL, Vaughan J, et al. Age and alarm symptoms do not predict endoscopic findings among patients with dyspepsia: a multicentre database study. Gut 2001; 49: 29-34.
35. McColl KE, el-Nujumi A, Murray L, et al. The Helicobacter pylori breath test: a surrogate marker for peptic ulcer disease in dyspeptic patients. Gut 1997; 40: 302-6.
36. Earlam R. A computerized questionnaire analysis of duodenal ulcer symptoms. Gastroenterology 1976; 71: 314-7.
37. Kang JY, Tay HH, Guan R. Chronic upper abdominal pain: site and radiation in various structural and functional disorders and the effect of various foods. Gut 1992; 33: 743-8.
38. Quan C, Talley NJ. Management of peptic ulcer disease not related to Helicobacter pylori or NSAIDs. Am J Gastroenterol 2002; 97: 2950-61.
39. Veldhuyzen van Zanten SJ, Flook N, Chiba N, et al. An evidence-based approach to the management of uninvestigated dyspepsia in the era of Helicobacter pylori. Canadian Dyspepsia Working Group. Can Med Assoc J 2000; 162 (12 Suppl.): S3-23.
40. Dyspepsia: managing adults in primary care. NICE clinical guidelines. Department of Health, UK, 2004. www.nice.org.uk.
41. Spiegel BM, Vakil NB, Ofman JJ. Dyspepsia management in primary care: a decision analysis of competing strategies. Gastroenterology 2002; 122: 1270-85.
42. Silverstein MD, Petterson T, Talley NJ. Initial endoscopy or empirical therapy with or without testing for Helicobacter pylori for dyspepsia: a decision analysis. Gastroenterology 1996; 110: 72-83.
43. Allison JE, Hurley LB, Hiatt RA, Levin TR, Ackerson LM, Lieu TA. A randomized controlled trial of test-and-treat strategy for Helicobacter pylori: clinical outcomes and health care costs in a managed care population receiving long-term acid suppression therapy for physician-diagnosed peptic ulcer disease. Arch Intern Med 2003; 163: 1165-71.
44. Ladabaum U, Fendrick AM, Glidden D, Scheiman JM. Helicobacter pylori test-and-treat intervention compared to usual care in primary care patients with suspected peptic ulcer disease in the United States. Am J Gastroenterol 2002; 97: 3007-14.
45. Manes G, Menchise A, De Nucci C, Balzano A. Empirical prescribing for dyspepsia: randomised controlled trial of test and treat versus omeprazole treatment. BMJ 2003; 326: 1118.
46. 2-receptor antagonist. Endoscopy 2002; 34: 524-6.
47. Smith T, Verzola E, Mertz H. Low yield of endoscopy in patients with persistent dyspepsia taking proton pump inhibitors. Gastrointest Endosc 2003; 58: 9-13.
48. Talley NJ. Yield of endoscopy in dyspepsia and concurrent treatment with pump inhibitors: the blind leading the blind? Gastrointest Endosc 2003; 58: 89-92.
49. Nietert PJ, Silverstein MD, Mokhashi MS, et al. Cost-effectiveness of screening a population with chronic gastroesophageal reflux. Gastrointest Endosc 2003; 57: 311-8.
50. Inadomi JM, Sampliner R, Lagergren J, Lieberman D, Fendrick AM, Vakil N. Screening and surveillance for Barrett esophagus in high-risk groups: a cost utility analysis. Ann Intern Med 2003; 138: 176-86.
51. Spechler SJ. Managing Barrett's oesophagus. Br Med J 2003; 326: 892-4.
52. Spechler SJ, Barr H. Screening and surveillance of Barrett's oesophagus: what is a cost-effective framework? [Review]. Aliment Pharmacol Ther 2004; 19 (Suppl. 2): 49-53.
53. Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999; 45: 172-80.
54. Eloubeidi MA, Provenzale D. Does this patient have Barrett's esophagus? The utility of predicting Barrett's esophagus at the index endoscopy. Am J Gastroenterol 1999; 94: 937-43.
55. Pandolfino JE, Richter JE, Ours T, Guardino JM, Chapman J, Kahrilas PJ. Ambulatory esophageal pH monitoring using a wireless system. Am J Gastroenterol 2003; 98: 740-9.
56. Ward EM, Devault KR, Bouras EP, et al. Successful oesophageal pH monitoring with a catheter-free system. Aliment Pharmacol Ther 2004; 19: 449-54.
57. Wayman J, Griffin SM, Campbell FC. Is functional dyspepsia largely explained by gastro-oesophageal disease? Baillières Clin Gastroenterol 1998; 12: 463-76.
58. Anonymous. American Gastroenterological Association medical position statement: guidelines on the use of esophageal pH recording. Gastroenterology 1996; 110: 1981.
59. Talley NJ, Piper DW. The association between non-ulcer dyspepsia and other gastrointestinal disorders. Scand J Gastroenterol 1985; 20: 896-900.
60. Fenster LF, Lonborg R, Thirlby RC, Traverso LW. What symptoms does cholecystectomy cure? Insights from an outcomes measurement project and review of the literature. Am J Surg 1995; 169: 533-8.
61. Jagannath SB, Singh VK, Cruz-Correa M, Canto MI, Kalloo AN. A long-term cohort study of outcome after cholecystectomy for chronic acalculous cholecystitis. Am J Surg 2003; 185: 91-5.
62. Buckles DC, Sarosiek I, McMillin C, McCallum RW. Delayed gastric emptying in gastroesophageal reflux disease: reassessment with new methods and symptomatic correlations. Am J Med Sci 2004; 327: 1-4.
63. Bredenoord AJ, Chial HJ, Camilleri M, Mullan BP, Murray JA. Gastric accommodation and emptying in evaluation of patients with upper gastrointestinal symptoms. Clin Gastroenterol Hepatol 2003; 1: 264-72.
64. Delgado-Aros S, Cremonini F, Talley NJ. Treatment of functional dyspepsia. Curr Treat Options Gastroenterol 2004; 7: 121-31.
65. Dent J, Jones R, Kahrilas P, Talley NJ. Management of gastrooesophageal reflux disease in general practice. BMJ 2001; 322: 344-7.
66. El-Serag HB, Sonnenberg A. Association of esophagitis and esophageal strictures with diseases treated with nonsteroidal anti-inflammatory drugs. Am J Gastroenterol 1997; 92: 52-6.
67. Potter JW, Saeian K, Staff D, et al. Eosinophilic esophagitis in adults: an emerging problem with unique esophageal features. Gastrointest Endosc 2004; 59: 355-61.
68. Dammann HG, Fuchs W, Richter G, et al. Lansoprazole versus omeprazole: Influence on meal-stimulated gastric acid secretion. Aliment Pharmacol Ther 1997; 11: 359-64.
69. Brummer RJ, Geerling BJ, Stockbrugger RW. Initial and chronic gastric acid inhibition by lansoprazole and omeprazole in relation to meal administration. Dig Dis Sci 1997: 42: 2132-7.
70. Thomson AB, Sinclair P, Matisko A, Rosen E, et al. Influence of food on the bioavailability of an enteric-coated tablet formulation of omeprazole 20 mg under repeated dose conditions. Can J Gastroenterol 1997; 11: 663-7.
71. Orr WC, Harnish MJ. The efficacy of omeprazole twice daily with supplemental H2 blockade at bedtime in the suppression of nocturnal oesophageal and gastric acidity. Aliment Pharmacol Ther 2003; 17: 1553-8.
72. Ours TM, Fackler WK, Richter JE, Vaezi MF. Nocturnal acid breakthrough: clinical significance and correlation with esophageal acid exposure. Am J Gastroenterol 2003; 98: 545-50.
73. Peghini PL, Katz PO, Castell DO. Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects. Gastroenterology 1998; 115: 1335-9.
74. Castell DO. Nocturnal acid breakthrough in perspective: Let's not throw out the baby with the bath water. Am J Gastroenterol 2003; 98: 517-8.
75. Collen MJ, Jensen RT. Idiopathic gastric acid hypersecretion. Comparison with Zollinger-Ellison syndrome. Dig Dis Sci 1994; 39: 1434-40.
76. Sharma P, Vakil N. Helicobacter pylori and reflux disease. Aliment Pharmacol Ther 2003; 17: 297-305.
77. Chong E, Ensom MH. Pharmacogenetics of the proton pump inhibitors: a systematic review. Pharmacotherapy 2003; 23: 460-71.
78. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection - the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002; 16: 167-80.
79. Moayyedi P, Deeks J, Talley NJ, Delaney B, Forman D. An update of the Cochrane systematic review of Helicobacter pylori eradication therapy in nonulcer dyspepsia: resolving the discrepancy between systematic reviews. Am J Gastroenterol 2003; 98: 2621-6.
80. Moayyedi P, Soo S, Deeks J, et al. Antacids, H2-receptor antagonists, prokinetics, bismuth and sucralfate therapy for non-ulcer dyspepsia [Systematic Review]. Aliment Pharmacol Ther 2003; 17: 1215-27.